September 22, 2020

Why Bring Liquid Biopsy Testing In-House? The Case for Millions in Cost Savings

We recently conducted a cost savings analysis for healthcare organizations interested in bringing liquid biopsy testing in-house. We discovered that, compared to outsourcing, in-house liquid biopsy testing with an actionable circulating tumor DNA (ctDNA) panel would enable healthcare organizations to attain substantial cost savings -- $2.7M per 1,000 cancer patients.


March 18, 2020

Our Commitment to Cancer Care During COVID-19

Healthcare systems and providers around the world are coming together and adapting quickly to deliver care to patients under extraordinary circumstances as the coronavirus pandemic evolves.

More Information at Your Fingertips

Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.

Learn More